|
시장보고서
상품코드
2049539
급성 골수성 백혈병 치료제 시장 보고서 : 치료법별, 약물 유형별, 투여 경로별, 지역별(2026-2034년)Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2026-2034 |
||||||
세계의 급성 골수성 백혈병 치료제 시장 규모는 2025년에 14억 8,520만 달러에 달했습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 10.11%로 성장하여 2034년까지 36억 2,630만 달러에 달할 것으로 예측하고 있습니다.
급성 골수성 백혈병(AML)은 비정상적인 세포의 급속한 증식을 일으키는 클론성 악성종양을 말합니다. 주로 골수와 백혈구(WBC)에 영향을 미치며, 피부색 변화, 호흡곤란, 피로감, 고열, 체중 감소, 잇몸 출혈, 코피 등의 증상이 특징입니다. 일반적으로 사용되는 AML 치료법으로는 화학요법, 면역요법, 표적치료, 호르몬요법, 수술적 치료 등이 있습니다. 이러한 치료법은 일반적으로 줄기세포 이식과 함께 시행하여 효과를 높이고 합병증을 최소화하며 신체의 면역 체계를 강화하는 데 도움이 됩니다.
전 세계적으로 백혈병의 유병률이 증가하고 있는 것은 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한, 이러한 질병에 걸리기 쉬운 고령 인구의 증가도 시장 성장을 촉진하고 있습니다. AML은 주로 혈액세포 생산량에 영향을 미치는 체내 유전자 돌연변이에 의해 발생합니다. 이와 함께 병용요법 및 표적 치료제의 보급과 암 치료에서 사용 가능한 옵션에 대한 인식이 높아짐에 따라 시장 성장에 기여하고 있습니다. 또한, 개선된 면역독소, 알킬화제, 단클론항체, 다제 내성 조절제의 출현도 시장 성장을 촉진하는 또 다른 주요 요인입니다. 이러한 치료법은 장기적인 효과, 높은 효능, 백혈병 세포의 조기 및 정확한 식별, 암 재발 가능성 감소를 가져옵니다. 이 외에도 종양학 분야의 광범위한 연구개발(R&D) 활동과 기존 헬스케어 인프라의 대폭적인 개선 등도 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 세계 급성 골수성 백혈병 치료제 시장은 지금까지 어떤 추세를 보였으며, 향후 몇 년 동안 어떤 추세를 보일 것인가?
- COVID-19는 세계 급성 골수성 백혈병 치료제 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 치료법별로 보면 시장은 어떻게 구분되는가?
- 약품 종류별 시장 현황은 어떠한가?
- 투여 경로별 시장 현황은 어떠한가?
- 이 산업의 가치사슬에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 급성 골수성 백혈병 치료제 시장의 구조는 무엇이며, 주요 플레이어는 누구인가?
- 업계 내 경쟁은 어느 정도 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 급성 골수성 백혈병 치료제 시장
제6장 시장 내역 : 치료 유형별
제7장 시장 내역 : 약물 유형별
제8장 시장 내역 : 투여 경로별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSM 26.06.10The global acute myeloid leukemia therapeutics market size reached USD 1,485.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,626.3 Million by 2034, exhibiting a growth rate (CAGR) of 10.11% during 2026-2034.
Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.
The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Treatment Type:
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-Metabolites
- Tyrosine Kinase Inhibitors
- Others
Breakup by Drug Type:
- Small Molecule Drugs
- Biopharmaceuticals
Breakup by Route of Administration:
- Oral
- Injectables
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Acute Myeloid Leukemia Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Cytarabine
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Anthracycline Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Alkylating Agents
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Anti-Metabolites
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Tyrosine Kinase Inhibitors
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Drug Type
- 7.1 Small Molecule Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Biopharmaceuticals
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Injectables
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbvie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Amgen Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bristol-Myers Squibb Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Celgene
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 SWOT Analysis
- 14.3.5 Roche Holding AG
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 Gilead Sciences Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Novartis AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi S.A.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Takeda Pharmaceutical Company Limited
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.1 Abbvie Inc.
